# BioCryst Pharmaceuticals (BCRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BCRX
## Company Profile
- Ticker: BCRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Small Molecule Drugs, Rare Disease
## Stock Data
- Close: 8.07 USD
- Market cap: 2119716584.3999999 USD
- Last updated: 2026-10-13
## Business Overview
### Rare-Disease Drug Development
BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders.
### ORLADEYO Commercial Franchise
ORLADEYO is an oral preventive therapy for hereditary angioedema and provides the company’s principal commercial foundation. Its once-daily oral profile differentiates it from injectable prophylactic options and supports BioCryst’s established presence in the HAE market.
### Navenibart in Hereditary Angioedema
Navenibart is a long-acting investigational treatment being evaluated in the pivotal ALPHA-ORBIT study for HAE. BioCryst retains core development responsibilities while licensing European commercial rights to Neopharmed Gentili.
### BCX17725 for Netherton Syndrome
BCX17725 is an investigational KLK5 inhibitor in Phase 1 development for Netherton syndrome. The program extends BioCryst’s small-molecule expertise into a rare genetic skin disorder with limited treatment options.
## Why The Stock Is Moving

As of Oct 13, 2026, BCRX closed down 3.47% at $8.07. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in the pivotal ALPHA-ORBIT navenibart study expected by the end of June 2026.
- Data from Part 4 of the BCX17725 Phase 1 trial expected by year-end 2026.
- U.S. regulatory filing for navenibart targeted by the end of 2027.

## Recent News
- 2026-10-05 11:00 EST — [BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth](https://biopharmsignal.com/news/BCRX/biocryst-announces-formation-of-scientific-advisory-board-to-drive-rare-disease--16991f5e) — Source: BioCryst Pharmaceuticals
- 2026-09-01 11:00 EST — [BioCryst to Present at Upcoming Investor Conference](https://biopharmsignal.com/news/BCRX/biocryst-to-present-at-upcoming-investor-conference-2f610d6d) — Source: BioCryst Pharmaceuticals
- 2026-08-05 11:00 EST — [BioCryst Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/BCRX/biocryst-reports-second-quarter-2026-financial-results-00d7eb2b) — Source: BioCryst Pharmaceuticals
- 2026-07-22 11:00 EST — [BioCryst to Report Second Quarter 2026 Financial Results on August 5](https://biopharmsignal.com/news/BCRX/biocryst-to-report-second-quarter-2026-financial-results-on-august-5-9520c4fa) — Source: BioCryst Pharmaceuticals
- 2026-07-15 11:00 EST — [BioCryst Appoints David W. Jenkins as Chief Scientific Officer](https://biopharmsignal.com/news/BCRX/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer-a24b8329) — Source: BioCryst Pharmaceuticals